Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 23)
- AngioDynamics, Inc. ANGO
- Arrowhead Pharmaceuticals, Inc. ARWR
- Avid Bioservices, Inc. CDMO
- Axonics, Inc. AXNX
- Century Therapeutics, Inc. Common Stock IPSC (went public June 18)
- Entera Bio Ltd. ENTX (announced positive mid-phase data for bone-building therapy)
- Citius Pharmaceuticals, Inc. CTXR
- Edwards Lifesciences Corporation EW
- Intra-Cellular Therapies, Inc. ITCI
- Intuitive Surgical, Inc. ISRG
- Ironwood Pharmaceuticals, Inc. IRWD
- Lantheus Holdings, Inc. LNTH
- OrthoPediatrics Corp. KIDS
- PAVmed Inc. PAVM
- ResMed Inc. RMD
- Vericel Corporation VCEL
- West Pharmaceutical Services, Inc. WST
Down In The Dumps
(Biotech Stocks Hitting 52-week Lows June 23)
- 4D Molecular Therapeutics, Inc. FDMT
- AbCellera Biologics Inc. ABCL
- Adicet Bio, Inc. ACET
- Allogene Therapeutics, Inc. ALLO
- Celyad Oncology SA CYAD
- Cullinan Oncology, Inc. CGEM
- ERYTECH Pharma S.A. ERYP
- Gain Therapeutics, Inc. GANX
- Galapagos NV GLPG (announced resignation of chief scientific officer)
- Gemini Therapeutics, Inc. GMTX (declined despite reporting positive mid-stage data for drug to treat advanced retinal disorder)
- Impel NeuroPharma, Inc. IMPL
- IMV Inc. IMV
- ORIC Pharmaceuticals, Inc. ORIC
- Pharming Group N.V. PHAR
Stocks In Focus
Viatris Gets Favorable Decision On EpiPen Lawsuit
Viatris VTRS announced that the U.S. District Court for the District of Kansas ruled, in substantial part, in Mylan's favor on the company's summary judgment motion in a class action related to the EpiPen Auto-Injector.
The company said it is pleased with the court's decision to dismiss all of the plaintiffs' claims under the federal RICO statute, which include claims asserted against Mylan's former CEO Heather Bresch. The court also dismissed claims alleging that Mylan foreclosed branded competition through rebate arrangements with pharmacy benefit managers.
Arcus Announces Positive Phase 2 Data For Antibody Combo Treatment Option For Lung Cancer
Arcus Biosciences, Inc. RCUS said at the first interim analysis of the three-arm Phase 2 ARC-7 study, both arms with domvanalimab-based combinations showed encouraging clinical activity, when given as an initial treatment to people with metastatic, PD-L1≥50% non-small cell lung cancer.
The zimberelimab monotherapy arm showed activity similar to that of marketed anti-PD-1 antibodies studied by other companies in this setting. At the time of data cut off, no unexpected safety signals were observed.
All three arms of the ARC-7 trial, and the ongoing ARC-10 Phase 3 registrational study, will continue to enroll as planned, the company said.
Arcus also said its partner Gilead Sciences, Inc. GILD has an exclusive option to co-develop and co-commercialize domvanalimab and will make a decision regarding opting into the anti-TIGIT program later this year.
The stock was jumping 19.53% to $27.97 premarket Thursday.
Merck-AstraZeneca's Lynparza Conditionally Approved For Treating Prostate Cancer In China
Merck & Co., Inc. MRK and AstraZeneca PLC AZN said Lynparza has been granted conditional approval in China as monotherapy for the treatment of adult patients with germline or somatic BRCA-mutated metastatic castration-resistant prostate cancer, who have progressed following prior treatment that included a new hormonal agent.
In premarket trading, Merck shares were adding 0.46% to $75.93 and AstraZeneca was moving up 0.78% to $58.43.
Karyopharm Gets Up to $100M Financing For R&D
Karyopharm Therapeutics Inc. KPTI announced the expansion of its royalty agreement with entities managed by HealthCare Royalty Management, for up to $100 million in new financing to support the ongoing development and commercialization of Xpovio, and for the clinical development of other programs, including eltanexor.
Xpovio is marketed in the U.S. for multiple hematologic malignancy indications and has received conditional marketing authorization by the European Commission for patients with heavily pretreated multiple myeloma. Eltanexor is currently being investigated for the treatment of patients with refractory myelodysplastic syndrome.
The stock was up 4.54% to $10.82 in premarket trading.
Applied Genetic Reports Positive Phase 1/2 Data For Gene Therapy To Treat Inherited Color Blindness
Applied Genetic Technologies Corporation AGTC announced 12-month data for adult patients and low dose pediatric patients in its Phase 1/2 clinical trials evaluated AAV gene therapy for achromatopsia, showing biologic activity based on improvements in visual sensitivity in the treated area.
The safety profile of the ophthalmic gene therapy platform remained favorable, the company added.
Applied Genetic said it intends to advance the ACHM B3 trial to the next stage of clinical development, premised on the positive data. The path forward for ACHM A3 will be determined after additional pediatric patient data and pre-clinical studies are available and can be evaluated, it added.
The stock was up 6.95% at $4.46 in premarket trading.
Biogen-Eisai's Investigational Alzheimer's Disease Drug Gets Breakthrough Therapy Designation
Biogen, Inc. BIIB and Eisai Co., Ltd. ESALY announced that the FDA has granted breakthrough therapy designation for lecanemab, an investigational anti-amyloid beta protofibril antibody for the treatment of Alzheimer's disease.
Roche's Wet AMD Therapy Accepted For Review With Priority Status
Roche Holding AG RHHBY announced that the FDA has accepted the company's biologics license application under priority review for a port delivery system with ranibizumab for the treatment of neovascular or wet age-related macular degeneration.
If approved, PDS would be a first-of-its-kind therapeutic approach, offering people living with nAMD an alternative to frequent eye injections of anti-vascular endothelial growth factor, the current standard of care, Roche said.
The FDA is expected to make a decision on approval by Oct. 23.
Lilly's Alzheimer's Therapy Gets Breakthrough Therapy Designation; Company To File BLA Later This Year
Eli Lilly and Company LLY said the FDA granted breakthrough therapy designation for donanemab, its investigational antibody therapy for Alzheimer's disease.
Lilly said it intends to submit a biologics license application for donanemab under the accelerated approval pathway later this year based on data from TRAILBLAZER-ALZ Phase 2 Study.
Lilly shares were up 8.25% to $235 in premarket trading.
4D Molecular Regains Full Rights to Gene Therapy To Treat Inherited Eye Disorder After Roche Terminates Licensing Deal
4D Molecular said it has received a notice of termination of the collaboration and license agreement by 4D-110 licensee Roche resulting in full rights to 4D-110 reverting to itself.
4D Molecular also reported positive preclinical data for 4D-110 in Choroideremia and 4D-125 for X-linked retinitis pigmentosa.
Neuronetics To Join Russell 2K Index
Neuronetics, Inc. STIM said the company will be added to the Russell 2000 Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the U.S. market opens on June 28, according to a preliminary list of additions posted June 4.
On The Radar
FDA's Oncologic Drugs Advisory Committee is scheduled to meet between 10:30 a.m. and 2:30 p.m. to discuss Incyte Corporation's INCY biologics license application for retifanlimab as a treatment option for adult patients with locally advanced or metastatic squamous carcinoma of the anal canal, who have progressed on or who are intolerant of platinum-based chemotherapy.
Fulcrum Therapeutics, Inc. FULC will present at the Facioscapulohumeral Muscular Dystrophy Society's International Research Congress data from its Phase 2b clinical trial of Losmapimod, a treatment for FSH muscular dystrophy that is intended to stop the expression of the DUX4 gene and slow the progression of symptoms.
Aethlon Medical, Inc. AEMD (after the close)
Monte Rosa Therapeutics, Inc., a biotech developing a portfolio of small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins, priced its initial public offering of 11.7 million shares of common stock at a public offering price of $19 per share. All of the shares are being offered by Monte Rosa. The shares are expected to begin trading on the Nasdaq under the ticker symbol "GLUE."
The gross proceeds of the offering are expected to be approximately $222.3 million.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.